EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
– PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21- – OBG: U.S. IND submission and initiation of Phase 2 dry eye study is planned in Q4:21; proof-of-concept study for persistent epithelial defects expected to initiate in Q4:21- – PP-001 for systemic indications: Phase…